Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model

• Published in: mBio Vol. 13; no. 1; p. e0304421
• Main Authors: Chiba, Shiho, Kiso, Maki, Nakajima, Noriko, Iida, Shun, Maemura, Tadashi, Kuroda, Makoto, Sato, Yuko, Ito, Mutsumi, Okuda, Moe, Yamada, Shinya, Iwatsuki-Horimoto, Kiyoko, Watanabe, Tokiko, Imai, Masaki, Armbrust, Tammy, Baric, Ralph S, Halfmann, Peter J, Suzuki, Tadaki, Kawaoka, Yoshihiro
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 01.02.2022
• Subjects: Animals; Antiviral Agents - pharmacology; COVID-19; COVID-19 Drug Treatment; Cricetinae; favipiravir; GS-441524; Lung; Mesocricetus; remdesivir; Research Article; SARS-CoV-2; Syrian hamster; Virology; Syrian hamster; SARS-CoV-2; GS-441524; remdesivir; favipiravir
• ISSN: 2150-7511; 2150-7511
• DOI: 10.1128/mbio.03044-21

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide since December 2019, causing coronavirus disease 2019 (COVID-19). Although vaccines for this virus have been developed rapidly, repurposing drugs approved to treat other diseases remains an invaluable treatment strategy. Here, we evaluated the inhibitory effects of drugs on SARS-CoV-2 replication in a hamster infection model and in assays. Favipiravir significantly suppressed virus replication in hamster lungs. Remdesivir inhibited virus replication , but was not effective in the hamster model. However, GS-441524, a metabolite of remdesivir, effectively suppressed virus replication in hamsters. Co-administration of favipiravir and GS-441524 more efficiently reduced virus load in hamster lungs than did single administration of either drug for both the prophylactic and therapeutic regimens; prophylactic co-administration also efficiently inhibited lung inflammation in the infected animals. Furthermore, pretreatment of hamsters with favipiravir and GS-441524 effectively protected them from virus transmission via respiratory droplets upon exposure to infected hamsters. Repurposing and co-administration of antiviral drugs may help combat COVID-19. During a pandemic, repurposing drugs that are approved for other diseases is a quick and realistic treatment option. In this study, we found that co-administration of favipiravir and the remdesivir metabolite GS-441524 more effectively blocked SARS-CoV-2 replication in the lungs of Syrian hamsters than either favipiravir or GS-441524 alone as part of a prophylactic or therapeutic regimen. Prophylactic co-administration also reduced the severity of lung inflammation. Moreover, co-administration of these drugs to naive hamsters efficiently protected them from airborne transmission of the virus from infected animals. Since both drugs are nucleotide analogs that interfere with the RNA-dependent RNA polymerases of many RNA viruses, these findings may also help encourage co-administration of antivirals to combat future pandemics.